Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily with ASACOL [mesalazine] 1.6g/day twice daily in the maintenance of remission in patients with ulcerative colitis.

Next Previous
X
Search
Trial Profile

A phase III, randomized multi-centre, double-blind, parallel group, active comparator study to compare the efficacy and safety of SPD476 (mesalazine) 2.4g/day once daily with ASACOL [mesalazine] 1.6g/day twice daily in the maintenance of remission in patients with ulcerative colitis.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire

    • Most Recent Events

    • 02 Nov 2012 Planned number of patients changed from 826 to 830.
    • 08 May 2012 Primary endpoint 'non-inferiority in endoscopic remission-rate at 6 months' has been met.
    • 18 Jul 2011 Mesalazine has been approved in the US for maintenance of remission of Ulcerative colitis, based on the results from this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top